Scotland's NICE dislikes GSK's Anoro

Share this article:

Scotland's version of NICE, the Scottish Medicines Consortium (SMC), says two COPD drugs are not worth the Scottish National Health Service's money.

Among the drugs Regulatory Focus found on the SMC's “not recommended” list were GlaxoSmithKline's Anoro (umeclidinium/vilantero) and Boehringer Ingelheim's Striverdi Respimat (olodaterol).

Share this article:
You must be a registered member of MMM to post a comment.

Does a health psychology approach hold the key to Rx adherence? In MM&M's latest Leadership Exchange Uncut eBook, industry stakeholders from the payer, provider, academic and pharma realms explore the "why" behind medicine taking. Access here.